OBIO

Orchestra Biomed Holdings Inc

Add to Watchlist

Advanced Chart

2.650

-0.220(-7.670%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

2.920

Open

2.800

VWAP

2.73

Vol

174.96K

Mkt Cap

101.53M

Low

2.650

Amount

477.40K

EV/EBITDA(TTM)

Total Shares

35.79M

57.44M

EV/OCF(TTM)

P/S(TTM)

40.05

Orchestra BioMed Holdings, Inc. is a biomedical innovation company seeking to provide solutions for unmet needs in procedure-based medicine. The Company’s flagship product candidates are Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of artery disease, the leading cause of mortality worldwide, and BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension, a significant risk factor for death worldwide. Virtue SAB is a drug/device combination product candidate for the treatment of artery disease designed to deliver an extended-release formulation of sirolimus, SirolimusEFR, during balloon angioplasty without the need for balloon coating or a permanent implant. BackBeat CNT is a bioelectronic treatment for hypertension that is designed to drive an immediate, substantial and persistent reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain the reduction.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

747.33K

-24.28%

716.67K

-7.88%

522.33K

-15.75%

Estimates Revision

The market is revising Downward the revenue expectations for Orchestra BioMed Holdings, Inc. (OBIO) for FY2025, with the revenue forecasts being adjusted by -35.38% over the past three months. During the same period, the stock price has changed by -52.51%.

Revenue Estimates for FY2025

Revise Downward

-35.38%

In Past 3 Month

Stock Price

Go Down

-52.51%

In Past 3 Month

3 Analyst Rating

403.02% Upside

Wall Street analysts forecast OBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OBIO is 13.33 USD with a low forecast of 12.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

403.02% Upside

Current: 2.650

Low

12.00

Averages

13.33

High

16.00

403.02% Upside

Current: 2.650

Low

12.00

Averages

13.33

High

16.00

Barclays

Matt Miksic

Buy

Maintains

$16 → $12

2025-05-05

New

Reason

Barclays

Matt Miksic

Price Target

$16 → $12

2025-05-05

New

Maintains

Buy

Reason

Barclays lowered the firm's price target on Orchestra BioMed to $12 from $16 and keeps an Overweight rating on the shares. The firm increased its loss estimates through 2027 to reflect the company's increased research and development spend over the next three years, with easing spending in the subsequent three years. The analyst cites lower group multiples, rather than concerns in the underlying business, for the target cut.

Chardan Capital

Keay Nakae

Strong Buy

Maintains

$20

2025-04-22

Reason

Chardan Capital

Keay Nakae

Price Target

$20

2025-04-22

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$14 → $12

2025-04-04

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$14 → $12

2025-04-04

Maintains

Strong Buy

Reason

Chardan Capital

Keay Nakae

Strong Buy

Maintains

$20

2025-04-01

Reason

Chardan Capital

Keay Nakae

Price Target

$20

2025-04-01

Maintains

Strong Buy

Reason

BTIG

Marie Thibault

Strong Buy

Initiates

$12

2025-03-20

Reason

BTIG

Marie Thibault

Price Target

$12

2025-03-20

Initiates

Strong Buy

Reason

BTIG analyst Marie Thibault initiated coverage of Orchestra BioMed with a Buy rating and $12 price target. Orchestra is a medical technology company with a "unique business model maximizing its expertise in research and development while partnering with large companies to bring new devices to market, the analyst tells investors in a research note. The firm says the company's first two products are focused on the large, underserved markets of hypertension and coronary artery disease. While Orchestra is still proving out its business model, there is "plenty to like with the approach," contends BTIG.

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$14

2025-03-10

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$14

2025-03-10

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Orchestra Biomed Holdings Inc (OBIO.O) is -1.43, compared to its 5-year average forward P/E of -2.80. For a more detailed relative valuation and DCF analysis to assess Orchestra Biomed Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.80

Current PE

-1.43

Overvalued PE

-0.15

Undervalued PE

-5.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.19

Current EV/EBITDA

-0.54

Overvalued EV/EBITDA

0.83

Undervalued EV/EBITDA

-3.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

57.36

Current PS

33.86

Overvalued PS

109.90

Undervalued PS

4.82

Financials

Annual

Quarterly

FY2024Q4

YoY :

-3.44%

253.00K

Total Revenue

FY2024Q4

YoY :

+33.62%

-16.68M

Operating Profit

FY2024Q4

YoY :

+26.03%

-16.16M

Net Income after Tax

FY2024Q4

YoY :

+16.67%

-0.42

EPS - Diluted

FY2024Q4

YoY :

+29.82%

-14.25M

Free Cash Flow

FY2024Q4

YoY :

-6.07%

77.08

Gross Profit Margin - %

FY2024Q4

YoY :

+16.50%

-1.95K

FCF Margin - %

FY2024Q4

YoY :

+30.52%

-6.39K

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 474.14% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

225.6K

USD

0-12

Months

0.0

USD

Bought

0-3

275.7K

USD

Months

3-6

48.0K

USD

Months

6-9

47.9K

USD

Months

0-12

21.6K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

238.2K

Volume

Months

6-9

3.0M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areBuying! The selling amount has increased 474.14% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

225.6K

USD

0-12

Months

0.0

USD

Bought

0-3

275.7K

USD

Months

3-6

48.0K

USD

Months

6-9

47.9K

USD

Months

0-12

21.6K

USD

Months

OBIO News & Events

Events Timeline

2025-05-07 (ET)

2025-05-07

08:33:11

Orchestra BioMed announces continued expansion of global property estate

2025-04-29 (ET)

2025-04-29

09:09:05

Orchestra BioMed receives approval of IDE to initiate Virtue Trial

2025-04-22 (ET)

2025-04-22

07:04:02

Orchestra BioMed receives FDA BDD for AVIM therapy

News

9.0

05-07Newsfilter

Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

6.0

05-05Benzinga

Barclays Maintains Overweight on Orchestra BioMed Hldgs, Lowers Price Target to $12

9.0

04-29Newsfilter

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon